Literature DB >> 19693464

Detection of intestinal bifidobacteria and lactobacilli in patients with Hirschsprung's disease associated enterocolitis.

Di-Hua Shen1, Cheng-Ren Shi, Jing-Jing Chen, Shi-Yao Yu, Yan Wu, Wen-Bo Yan.   

Abstract

BACKGROUND: The etiology of Hirschsprung's disease associated enterocolitis (HAEC) is unknown. Previous investigations have suggested that several factors such as dilation of proximal bowel, changes in colonic mucosal defence, and overgrowth of toxigenic bacteria may be related with it. This study was to quantify bifidobacteria and lactobacilli in the feces of Hirschsprung's disease (HD) patients with or without enterocolitis and those of normal children.
METHODS: Fresh stool specimens were collected at the first three days of the admission from 30 HD patients (aged 2 weeks to 2 years) and 15 healthy age-matched non-HD patients in the morning once a day for at least three days. All of them have not been given probiotics or antibiotics at least 7 days before stool collection. Hematoxylin-eosin and acetylcholinesterase histochemical staining on rectal biopsies of patients with HD confirmed the diagnosis of HD in all 30 patients. The 30 HD patients were divided into two groups based on the clinical history of enterocolitis: the HAEC group (n=10) and HD group (n=20). Fecal bifidobacteria and lactobacilli were consecutively quantified by SYBR Green I-based real-time PCR assay. Data were analyzed using SAS v. 12.6 for Windows. All tests were two-tailed, and P values <0.05 were considered statistically significant.
RESULTS: The mean levels of bifidobacteria were 7.35+/-0.59, 8.16+/-1.17, and 8.35+/-0.74 in the HAEC, HD and control groups, respectively. The bifidobacteria colonization levels were lower in the HAEC group than in the HD and control groups (P<0.05, P<0.001 respectively). The mean level of lactobacilli in the HAEC (5.51+/-0.65) and HD groups (5.87+/-0.78) was significantly lower than that in the control group (6.39+/-0.56) (P<0.05). But there was no difference in log numbers of lactobacilli between HAEC and HD groups (P>0.05).
CONCLUSIONS: The scarcity of bifidobacteria and lactobacilli in HAEC patients may result in a decrease in epithelial barrier function and be a predisposing factor in the development of HAEC. This decline suggests that treatment with probiotics or prebiotics may be beneficial in these individuals. Further research will focus on whether probiotics can decrease the incidence of HAEC.

Entities:  

Mesh:

Year:  2009        PMID: 19693464     DOI: 10.1007/s12519-009-0038-x

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  24 in total

1.  An enteral formula containing fish oil, indigestible oligosaccharides, gum arabic and antioxidants affects plasma and colonic phospholipid fatty acid and prostaglandin profiles in pigs.

Authors:  J M Campbell; G C Fahey; C A Lichtensteiger; S J Demichele; K A Garleb
Journal:  J Nutr       Date:  1997-01       Impact factor: 4.798

2.  Bifidobacterial diversity in human feces detected by genus-specific PCR and denaturing gradient gel electrophoresis.

Authors:  R M Satokari; E E Vaughan; A D Akkermans; M Saarela; W M de Vos
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

3.  Enterocolitis in Hirschsprung's disease: a controlled study of the etiologic role of Clostridium difficile.

Authors:  D F Thomas; D S Fernie; R Bayston; L Spitz; H H Nixon
Journal:  J Pediatr Surg       Date:  1986-01       Impact factor: 2.545

4.  Defective white blood cell function in Hirschsprung's disease: a possible predisposing factor to enterocolitis.

Authors:  D Wilson-Storey; W G Scobie; J A Raeburn
Journal:  J R Coll Surg Edinb       Date:  1988-08

5.  The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession.

Authors:  G Reuter
Journal:  Curr Issues Intest Microbiol       Date:  2001-09

6.  Molecular epidemiological study of vertical transmission of vaginal Lactobacillus species from mothers to newborn infants in Japanese, by arbitrarily primed polymerase chain reaction.

Authors:  Yoshiko Matsumiya; Naoki Kato; Kunitomo Watanabe; Haru Kato
Journal:  J Infect Chemother       Date:  2002-03       Impact factor: 2.211

7.  Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA.

Authors:  Hans G H J Heilig; Erwin G Zoetendal; Elaine E Vaughan; Philippe Marteau; Antoon D L Akkermans; Willem M de Vos
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

8.  Impaired gastrointestinal mucosal defense in Hirschsprung's disease: a clue to the pathogenesis of enterocolitis?

Authors:  D Wilson-Storey; W G Scobie
Journal:  J Pediatr Surg       Date:  1989-05       Impact factor: 2.545

9.  Microbiota composition of the intestinal mucosa: association with fecal microbiota?

Authors:  Arthur C Ouwehand; Seppo Salminen; Taina Arvola; Tarja Ruuska; Erika Isolauri
Journal:  Microbiol Immunol       Date:  2004       Impact factor: 1.955

10.  Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates.

Authors:  Jinjin Chen; Wei Cai; Yi Feng
Journal:  Clin Nutr       Date:  2007-05-15       Impact factor: 7.324

View more
  16 in total

Review 1.  Hirschsprung-associated enterocolitis: pathogenesis, treatment and prevention.

Authors:  Farokh R Demehri; Ihab F Halaweish; Arnold G Coran; Daniel H Teitelbaum
Journal:  Pediatr Surg Int       Date:  2013-09       Impact factor: 1.827

Review 2.  Recent developments in Hirschsprung's-associated enterocolitis.

Authors:  Elizabeth M Pontarelli; Henri R Ford; Christopher P Gayer
Journal:  Curr Gastroenterol Rep       Date:  2013-08

3.  A pilot study characterizing longitudinal changes in fecal microbiota of patients with Hirschsprung-associated enterocolitis.

Authors:  Kristopher D Parker; Jessica L Mueller; Maggie Westfal; Allan M Goldstein; Naomi L Ward
Journal:  Pediatr Surg Int       Date:  2022-08-11       Impact factor: 2.003

Review 4.  Probiotics for the prevention of Hirschsprung-associated enterocolitis.

Authors:  Fan Mei; Mei Wu; Li Zhao; Kaiyan Hu; Qianqian Gao; Fei Chen; Joey Sw Kwong; Yanan Wang; Xi Ping Shen; Bin Ma
Journal:  Cochrane Database Syst Rev       Date:  2022-04-26

Review 5.  Current understanding of Hirschsprung-associated enterocolitis: Pathogenesis, diagnosis and treatment.

Authors:  Ruth A Lewit; Korah P Kuruvilla; Ming Fu; Ankush Gosain
Journal:  Semin Pediatr Surg       Date:  2022-04-08       Impact factor: 1.900

6.  Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung's disease.

Authors:  Joseph F Pierre; Amanda J Barlow-Anacker; Christopher S Erickson; Aaron F Heneghan; Glen E Leverson; Scot E Dowd; Miles L Epstein; Kenneth A Kudsk; Ankush Gosain
Journal:  J Pediatr Surg       Date:  2014-08       Impact factor: 2.545

Review 7.  Hirschsprung-associated enterocolitis: prevention and therapy.

Authors:  Philip K Frykman; Scott S Short
Journal:  Semin Pediatr Surg       Date:  2012-11       Impact factor: 2.754

8.  Altered fecal short chain fatty acid composition in children with a history of Hirschsprung-associated enterocolitis.

Authors:  Farokh R Demehri; Philip K Frykman; Zhi Cheng; Chunhai Ruan; Tomas Wester; Agneta Nordenskjöld; Akemi Kawaguchi; Thomas T Hui; Anna L Granström; Vince Funari; Daniel H Teitelbaum
Journal:  J Pediatr Surg       Date:  2015-10-22       Impact factor: 2.545

Review 9.  Probiotics for the prevention of Hirschsprung-associated enterocolitis: a systematic review and meta-analysis.

Authors:  H Nakamura; T Lim; P Puri
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

10.  Prospective study reveals a microbiome signature that predicts the occurrence of post-operative enterocolitis in Hirschsprung disease (HSCR) patients.

Authors:  Weibing Tang; Yang Su; Chen Yuan; Yuqing Zhang; Lingling Zhou; Lei Peng; Pin Wang; Guanglin Chen; Yang Li; Hongxing Li; Zhengke Zhi; Hang Chang; Bo Hang; Jian-Hua Mao; Antoine M Snijders; Yankai Xia
Journal:  Gut Microbes       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.